多发性硬化症疾病活动,多个生物标志物评分疾病活动和多发性硬化症治疗反应
Alexandru Tatomir1,2, Freidrich Anselmo1, Dallas Boodhoo1
1Department of Neurology, University of Maryland, School of Medicine, Baltimore, MD, United States.
Frontiers in immunology
|July 12, 2024
概括
这项试点研究使用多种生物标志物开发了MS疾病活性 (MSDA) 评分,以预测复发性复发性多发性硬化症 (RRMS) 患者的复发和治疗反应. 在监测疾病活动和治疗反应方面,MSDA得分显示出有前途.
科学领域:
- 神经免疫学 神经免疫学
- 生物标志物发现发现
- 临床试验 临床试验
背景情况:
- 复发性复发性多发性硬化症 (RRMS) 需要定期评估疾病活动以获得最佳结果.
- 反映MS致病性的生物标志物对于测量疾病活性至关重要.
- 现有的方法可能无法完全捕捉MS的动态疾病变化.
研究的目的:
- 开发和评估一种新的MS病活动 (MSDA) 评分.
- 评估MSDA评分能够预测RRMS患者的复发和对格拉提拉乙酸盐 (GA) 治疗反应的能力.
- 为了确定MSDA得分是否与临床残疾指标相关.
主要方法:
- 将多个生物标志物 (RGC-32,FasL,IL-21,SIRT1,p-SIRT1,JNK1 p54) 结合在一起,形成一个MSDA评分.
- 为每个生物标志物定义了截止值,以赋予 +1 或 -1 值.
- 基于生物标志物值计算的MSDA得分,以表明复发/不反应或稳定/反应.
- 与扩展残疾状况量表 (EDSS) 相关联的MSDA分数.
主要成果:
- 来自四个或六个生物标志物的MSDA分数显示出高灵敏度和特异性.
- MSDA分数与扩展残疾状况量表有显著的相关性.
- 开发的MSDA得分有效地区分了复发/没有反应的患者和稳定/对GA有反应的患者.
结论:
- 在MSDA得分显示的潜力作为一个有价值的工具,监测MS患者的治疗反应.
- MSDA测试可以帮助评估MS管理中临床上具有挑战性的情况.
- 需要进行更大规模的研究来证实这些有希望的发现,并验证MSDA评分的临床实用性.
相关概念视频
Cross-reactivity
28.7K
Overview
28.7K
Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Drug Toxicity: Allergic Reactions
209
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
209
Bioactivation and Tissue Toxicity
151
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
151
Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Hypersensitivity Reactions: Immune-Complex Reactions
269
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
269


